NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 PLTR
Palantir
-- 83.890 GOOG
Alphabet-C
-- 162.670 
NEWS
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Tuesday, 10th December at 8:00 am
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
- These data confirm luvelta's robust response rate in patients with late-stage ovarian cancer expressing a broad range of folate receptor alpha (FRα) -
- Neutropenia well-managed; no new safety findings -
- Luvelta is positioned for an Accelerated Approval application in mid-2027 -
Tuesday, 10th December at 8:00 am
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
- These data confirm luvelta's robust response rate in patients with late-stage ovarian cancer expressing a broad range of folate receptor alpha (FRα) -
- Neutropenia well-managed; no new safety findings -
- Luvelta is positioned for an Accelerated Approval application in mid-2027 -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment